-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the IPO prospectus of Baili Tianheng Science and Technology Innovation Board was officially released
.
According to the prospectus, the IPO plans to raise 1.
422 billion yuan, which will be used for the industrialization of antibody drugs, clinical research of antibody drugs, and the research and development of innovative antibody drugs in the field of tumor treatment
.
It can be seen from the above that the IPO of Baili Tianheng Science and Technology Innovation Board plans to raise 1.
422 billion yuan, all of which will be used for antibody drug research and development
.
The industry believes that this is the epitome of Baili Tianheng's accelerating deployment in the field of biopharmaceuticals
.
It is understood that Baili Tianheng started with the business of chemical generic drugs and Chinese patent medicines, but since 2011 it has been deploying the global innovative biological medicine field
.
In the prospectus, it clearly stated that the company will use the cash flow generated by the chemical medicine preparation and Chinese patent medicine preparation business to support and feed back the company's innovative biological medicine research and development
.
In addition, it is worth noting that as of the date of signing the prospectus, Baili Tianheng has 16 core innovative biopharmaceuticals under development with global rights, of which 7 have entered the clinical research stage, and 9 candidate biologics have entered the preclinical stage.
Pharmacology, toxicology and other research stages
.
The types of drugs cover different types such as bi/multispecific antibodies, ADC drugs, and fusion proteins
.
In fact, Baili Tianheng's fund-raising to develop antibody drugs is a microcosm of the industry's accelerated deployment in the field of biopharmaceuticals
.
In recent years, with the continuous expansion of the domestic biopharmaceutical market, innovative R&D companies in the biopharmaceutical chain are beginning to accelerate their deployment in the biopharmaceutical field
.
It is understood that due to the high technical difficulty and large R&D investment costs, domestic pharmaceutical companies have been late in the deployment of biological drugs, and the market often shows a pattern of monopolization of original research drugs
.
However, in recent years, with the expiration of patents for some original research drugs and the continuous expansion of the biopharmaceutical market, many pharmaceutical companies in China have accelerated their deployment in the biopharmaceutical field
.
Nuocheng Jianhua is an innovative biopharmaceutical company with independent research and development capabilities as its core driving force.
In September, Nuocheng Jianhua's IPO application has been accepted, and it plans to raise 4 billion yuan.
.
Among them, 2.
151 billion yuan will be used for new drug research and development projects, accounting for 53.
78% of the total funds raised, and the remaining funds will be used for drug research and development platform upgrade projects, marketing network construction projects, information construction projects and supplementary working capital
.
At present, with the continuous investment and deployment of pharmaceutical companies in the field of biopharmaceuticals, the achievements of domestic biopharmaceuticals have also begun to emerge
.
On August 4, Anke Biological announced that its application for marketing authorization of recombinant human HER2 monoclonal antibody for injection was accepted by the State Food and Drug Administration
.
On August 5, Paimrizumab, which was jointly developed by Kangfang Biotechnology and Chia Tai Tianqing, was also approved for listing, becoming the fifth domestically produced PD-1 approved for listing
.
In general, in order to promote the development of the domestic pharmaceutical industry, the policy orientation of China's pharmaceutical reform is accelerating its tilt towards innovative drugs.
Among many innovative drugs, there is great development prospects, and the technological level is smaller than that of the medical power.
The track is the biopharmaceutical
.
According to the current development trend, the industry predicts that by 2025, the size of China's biopharmaceutical market may reach 833.
2 billion yuan
.
.
According to the prospectus, the IPO plans to raise 1.
422 billion yuan, which will be used for the industrialization of antibody drugs, clinical research of antibody drugs, and the research and development of innovative antibody drugs in the field of tumor treatment
.
It can be seen from the above that the IPO of Baili Tianheng Science and Technology Innovation Board plans to raise 1.
422 billion yuan, all of which will be used for antibody drug research and development
.
The industry believes that this is the epitome of Baili Tianheng's accelerating deployment in the field of biopharmaceuticals
.
It is understood that Baili Tianheng started with the business of chemical generic drugs and Chinese patent medicines, but since 2011 it has been deploying the global innovative biological medicine field
.
In the prospectus, it clearly stated that the company will use the cash flow generated by the chemical medicine preparation and Chinese patent medicine preparation business to support and feed back the company's innovative biological medicine research and development
.
In addition, it is worth noting that as of the date of signing the prospectus, Baili Tianheng has 16 core innovative biopharmaceuticals under development with global rights, of which 7 have entered the clinical research stage, and 9 candidate biologics have entered the preclinical stage.
Pharmacology, toxicology and other research stages
.
The types of drugs cover different types such as bi/multispecific antibodies, ADC drugs, and fusion proteins
.
In fact, Baili Tianheng's fund-raising to develop antibody drugs is a microcosm of the industry's accelerated deployment in the field of biopharmaceuticals
.
In recent years, with the continuous expansion of the domestic biopharmaceutical market, innovative R&D companies in the biopharmaceutical chain are beginning to accelerate their deployment in the biopharmaceutical field
.
It is understood that due to the high technical difficulty and large R&D investment costs, domestic pharmaceutical companies have been late in the deployment of biological drugs, and the market often shows a pattern of monopolization of original research drugs
.
However, in recent years, with the expiration of patents for some original research drugs and the continuous expansion of the biopharmaceutical market, many pharmaceutical companies in China have accelerated their deployment in the biopharmaceutical field
.
Nuocheng Jianhua is an innovative biopharmaceutical company with independent research and development capabilities as its core driving force.
In September, Nuocheng Jianhua's IPO application has been accepted, and it plans to raise 4 billion yuan.
.
Among them, 2.
151 billion yuan will be used for new drug research and development projects, accounting for 53.
78% of the total funds raised, and the remaining funds will be used for drug research and development platform upgrade projects, marketing network construction projects, information construction projects and supplementary working capital
.
At present, with the continuous investment and deployment of pharmaceutical companies in the field of biopharmaceuticals, the achievements of domestic biopharmaceuticals have also begun to emerge
.
On August 4, Anke Biological announced that its application for marketing authorization of recombinant human HER2 monoclonal antibody for injection was accepted by the State Food and Drug Administration
.
On August 5, Paimrizumab, which was jointly developed by Kangfang Biotechnology and Chia Tai Tianqing, was also approved for listing, becoming the fifth domestically produced PD-1 approved for listing
.
In general, in order to promote the development of the domestic pharmaceutical industry, the policy orientation of China's pharmaceutical reform is accelerating its tilt towards innovative drugs.
Among many innovative drugs, there is great development prospects, and the technological level is smaller than that of the medical power.
The track is the biopharmaceutical
.
According to the current development trend, the industry predicts that by 2025, the size of China's biopharmaceutical market may reach 833.
2 billion yuan
.
